ReviewDialogues in clinical neuroscience2009
Biological markers for early detection and pharmacological treatment of Alzheimer's disease.
Review in Dialogues in clinical neuroscience, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Demystifying the Role of Neuroinflammatory Mediators as Biomarkers for Diagnosis, Prognosis, and Treatment of Alzheimer's Disease: A Review.ACS pharmacology & translational science · 2024Review
- Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?Cost effectiveness and resource allocation : C/E · 2023Article
- Article
- Lipid Metabolism in Late-Onset Alzheimer's Disease Differs from Patients Presenting with Other Dementia Phenotypes.International journal of environmental research and public health · 2019Article
- Dysregulated Urinary Arginine Metabolism in Older Adults With Amnestic Mild Cognitive Impairment.Frontiers in aging neuroscience · 2019Article
- Deciphering post-translational modification codes.FEBS letters · 2013Review
- Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias.European archives of psychiatry and clinical neuroscience · 2012Review
- Cost-effectiveness of magnetic resonance imaging with a new contrast agent for the early diagnosis of Alzheimer's disease.PloS one · 2012Article
- Review
- Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease.Current Alzheimer research · 2012Review
- Article
- The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease.Neurobiology of learning and memory · 2011Review
- APP transgenic mice: their use and limitations.Neuromolecular medicine · 2011Review
- Biomarkers in Alzheimer's disease: past, present and future.Biomarkers in medicine · 2010Review
- Blood-based biomarkers of microvascular pathology in Alzheimer's disease.Experimental gerontology · 2010Review
- Total and phosphorylated tau protein as biological markers of Alzheimer's disease.Experimental gerontology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of biological markers in the clinical management of Alzheimer's disease (AD) will not only improve diagnosis relating to early detection of neuropathology with underlying molecular mechanisms, but also provides tools for the assessment of objective treatment benefits. In this review, we identify a number of in vivo neurochemistry and neuroimaging techniques, which can reliably assess aspects of physiology, pathology, chemistry, and neuroanatomy of AD, and hold promise as meaningful biomarkers in the early diagnostic process, as well as for the tracking of disease-modifying pharmacological effects. These neurobiological measures appear to relate closely to pathophysiological, neuropathological, and clinical data, such as hyperphosphorylation of tau, abeta metabolism, lipid peroxidation, pattern and rate of atrophy, loss of neuronal integrity, and functional and cognitive decline, as well as risk of future decline. As a perspective, the important role of biomarkers in the development of innovative drug treatments for AD and the related regulatory process is discussed.
Indexed as
Identifiers
19585950PMC3181918W2140983748What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.